ClinicalTrials.gg
CompletedNCT06347133MUIR-3Updated Sep 25, 2026

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

A Phase 3 interventional study of Plozasiran Injection and Placebo in Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Completed at 235 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Arrowhead Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,456
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.

Enrollment
3rd of 145
1,456 · median 52
Started
2024
with 6 others
Phase 3
27 of 150
1 open now
Registered
136th of 150
by date
Lead sponsor
6 of 150
Arrowhead Pharmaceuticals

Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 3rd largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2024, is one of 27 in phase 3, and was the 136th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertriglyceridemia with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, or nonpregnant (who do not plan to become pregnant) nonlactating females, who are ≥18 years of age at screening
  • Established diagnosis of hypertriglyceridemia (HTG) and prior documented evidence (medical history) of mean fasting TG level ≥150 mg/dL (≥1.69 mm/L) and ≤499 mg/dL (≤5.64 mmol/L)
  • Mean fasting TG level ≥150 mg/dL (≥1.69 mmol/L) and ≤499 mg/dL (≤5.64 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
  • Fasting low density lipoprotein-cholesterol (LDL-C) ≤ 130 mg/dL (≤3.37 mmol/L) at screening
  • Screening ≤9.0%
  • Willing to follow diet counseling and maintain a stable low-fat diet
  • Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due a previous adverse reaction associated with, attributed to, or caused by specific drug) prior to collection of qualifying TG levels.

Exclusion criteria

Exclusion Criteria:

  • Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of drug and inclisiran must be separated by at least 4 weeks.
  • Use of any other hepatocyte targeted siRNA or antisense Oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer
  • Acute pancreatitis within 4 weeks prior to screening
  • >45 kg/m\^2

Note: Additional Inclusion/Exclusion criteria may apply per protocol

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,456 participants (actual)

Study arms

  • Experimental
    Plozasiran Injection

    4 doses of plozasiran by subcutaneous (sc) injection

    Drug: Plozasiran Injection

  • Placebo comparator
    Placebo

    calculated volume to match active treatment by sc injection

    Drug: Placebo

Interventions

  • ARO-APOC3 Injection

    Also known as: ARO-APOC3

  • DrugPlacebo

    sterile normal saline (0.9% NaCl)

06

What researchers measure

Primary outcomes

  1. Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Percent Change in Fasting Serum TG Levels from Baseline to Month 10 Compared to Placebo

    Time frame: Baseline, Month 10

  2. Proportion of Participants who Achieve Fasting TG Levels of <150 mg/dL (<1.69 mmol/L) at Month 12 Compared to Placebo

    Time frame: Month 12

  3. Percent change in remnant cholesterol (VLDL-C) from baseline to Month 12 compared to placebo.

    Time frame: Baseline, Month 12

  4. Percent change in non-HDL-C from baseline to Month 12 compared to placebo

    Time frame: Baseline, Month 12

  5. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Over Time through Month 12 as Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  6. Incidence Rates of New-Onset Diabetes Mellitus (NODM) Throughout the Course of Treatment

    Time frame: From first dose of study drug through Month 12

  7. Incidence Rates of Impaired Glucose Tolerance Throughout the Course of Treatment

    Time frame: From first dose of study drug through Month 12

  8. Incidence Rates of Worsening of Existing Diabetes Throughout the Course of Treatment

    Time frame: From first dose of study drug through Month 12

  9. Change from Baseline in Hemoglobin A1c (HbA1c) and Other Glycemic Control Parameters During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  10. Change from Baseline in Fasting Blood Glucose During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  11. Change from Baseline in C-peptide During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  12. Change from Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  13. Change from Baseline in Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) Associated with Worsening Glycemic Control During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  14. Initiation of New Medication for Hyperglycemia Among Study Participants Not Known to Have Pre-existing Diabetes Mellitus During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  15. Adjudicated Major Adverse Cardiovascular Events (MACE) Rates During the Treatment Period Compared to Placebo

    Time frame: From first dose of study drug through Month 12

  16. Incidence of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12

    Time frame: From first dose of study drug through Month 12

  17. Titers of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12

    Time frame: From first dose of study drug through Month 12

07

Study locations

235 sites
  • Research Site 1
    Birmingham, Alabama 35205, United States
  • Research Site 2
    Mobile, Alabama 36604, United States
  • Research Site 3
    Beverly Hills, California 90211, United States
  • Research Site 4
    Canoga Park, California 91303, United States
  • Research Site 5
    Garden Grove, California 92844, United States
  • Research Site 6
    Huntington Beach, California 92648, United States
  • Research Site 7
    Lake Forest, California 92630, United States
  • Research Site 8
    Lincoln, California 95648, United States
  • Research Site 9
    Long Beach, California 90822, United States
  • Research Site 10
    Montclair, California 91763, United States
  • Research Site 11
    Oxnard, California 93030, United States
  • Research Site 12
    Redding, California 96001, United States
  • Research Site 13
    Van Nuys, California 91402, United States
  • Research Site 14
    Colorado Springs, Colorado 80909, United States
  • Research Site 15
    Clearwater, Florida 33756, United States
  • Research Site 16
    Hialeah, Florida 33016, United States
  • Research Site 17
    Lake City, Florida 32055, United States
  • Research Site 18
    Miami Lakes, Florida 33014, United States
  • Research Site 19
    Mt. Dora, Florida 32757, United States
  • Research Site 20
    North Miami Beach, Florida 33162, United States
  • Research Site 21
    Orlando, Florida 32825, United States
  • Research Site 22
    Pensacola, Florida 32503, United States
  • Research Site 23
    Sarasota, Florida 34239, United States
  • Research Site 24
    Tamarac, Florida 33321, United States
  • Research Site 25
    Lawrenceville, Georgia 30044, United States
  • Research Site 26
    Macon, Georgia 31210, United States
  • Research Site 27
    Savannah, Georgia 31406, United States
  • Research Site 28
    Sugar Hill, Georgia 30518, United States
  • Research Site 29
    Park Ridge, Illinois 60068, United States
  • Research Site 30
    Elkhart, Indiana 46514, United States
  • Research Site 31
    Indianapolis, Indiana 46290, United States
  • Research Site 32
    South Bend, Indiana 46617, United States
  • Research Site 33
    Overland Park, Kansas 66211, United States
  • Research Site 34
    Topeka, Kansas 66606, United States
  • Research Site 35
    Louisville, Kentucky 40202, United States
  • Research Site 36
    Zachary, Louisiana 70791, United States
  • Research Site 37
    Annapolis, Maryland 21401, United States
  • Research Site 38
    Baltimore, Maryland 21229, United States
  • Research Site 39
    Flint, Michigan 48532, United States
  • Research Site 40
    Minneapolis, Minnesota 55455, United States
  • Research Site 41
    Olive Branch, Mississippi 38654, United States
  • Research Site 42
    Jefferson City, Missouri 65109, United States
  • Research Site 43
    St Louis, Missouri 63136, United States
  • Research Site 44
    Norfolk, Nebraska 68701, United States
  • Research Site 46
    Omaha, Nebraska 68114, United States
  • Research Site 45
    Omaha, Nebraska 68144, United States
  • Research Site 47
    Las Vegas, Nevada 89119, United States
  • Research Site 48
    Summit, New Jersey 07901, United States
  • Research Site 52
    New York, New York 10016, United States
  • Research Site 51
    New York, New York 10029, United States
  • Research Site 53
    Riverhead, New York 11901, United States
  • Research Site 54
    Rochester, New York 14642, United States
  • Research Site 49
    The Bronx, New York 10455, United States
  • Research Site 50
    The Bronx, New York 10461, United States
  • Research Site 55
    Vestal, New York 13850, United States
  • Research Site 56
    Asheboro, North Carolina 27203, United States
  • Research Site 57
    Morehead City, North Carolina 28557, United States
  • Research Site 58
    Wilmington, North Carolina 28412, United States
  • Research Site 59
    Winston-Salem, North Carolina 27157, United States
  • Research Site 60
    Beavercreek, Ohio 45431, United States
  • Research Site 61
    Cincinnati, Ohio 45267, United States
  • Research Site 63
    Columbus, Ohio 43210, United States
  • Research Site 62
    Columbus, Ohio 43214, United States
  • Research Site 64
    Norman, Oklahoma 73072, United States
  • Research Site 66
    Oklahoma City, Oklahoma 73111, United States
  • Research Site 65
    Oklahoma City, Oklahoma 73112, United States
  • Research Site 67
    Horsham, Pennsylvania 19044, United States
  • Research Site 68
    Newport, Pennsylvania 17074, United States
  • Research Site 69
    Newport, Pennsylvania 17074, United States
  • Research Site 70
    Philadelphia, Pennsylvania 19104, United States
  • Research Site 71
    Wilkes-Barre, Pennsylvania 18711, United States
  • Research Site 72
    Fort Mill, South Carolina 29707, United States
  • Research Site 73
    Greenville, South Carolina 29607, United States
  • Research Site 74
    Chattanooga, Tennessee 37411, United States
  • Research Site 75
    Powell, Tennessee 37849, United States
  • Research Site 76
    El Paso, Texas 79905, United States
  • Research Site 77
    Fort Worth, Texas 76132, United States
  • Research Site 86
    Houston, Texas 77029, United States
  • Research Site 84
    Houston, Texas 77030, United States
  • Research Site 85
    Houston, Texas 77030, United States
  • Research Site 78
    Houston, Texas 77040, United States
  • Research Site 80
    Houston, Texas 77061, United States
  • Research Site 83
    Houston, Texas 77074, United States
  • Research Site 82
    Houston, Texas 77079, United States
  • Research Site 79
    Houston, Texas 77090, United States
  • Research Site 81
    Houston, Texas 77095, United States
  • Research Site 87
    Laredo, Texas 78041, United States
  • Research Site 88
    Missouri City, Texas 77459, United States
  • Research Site 89
    Plano, Texas 75093, United States
  • Research Site 90
    San Antonio, Texas 78230, United States
  • Research Site 91
    Sugar Land, Texas 77479, United States
  • Research Site 92
    Tomball, Texas 77375, United States
  • Research Site 93
    Victoria, Texas 77901, United States
  • Research Site 94
    Bountiful, Utah 84010, United States
  • Research Site 95
    St. George, Utah 84790, United States
  • Research Site 96
    Manassas, Virginia 20110, United States
  • Research Site 97
    Seattle, Washington 98109, United States
  • Research Site 102
    CABA, Buenos Aires 1128, Argentina
  • Research Site 100
    CABA, Buenos Aires 1417, Argentina
  • Research Site 103
    Ciudad Autonoma Buenos Aires, Buenos Aires C1430CKE, Argentina

Showing the first 100 of 235 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jun 2026, 24 months.

Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's 24 months is close to that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 4, 2024
StartActual
May 21, 2024
Primary completionActual
Jun 1, 2026
CompletionActual
Sep 8, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    + 3 other changes: identifiers, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06347133
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
May 21, 2024
Primary completion
Jun 1, 2026
Completion
Sep 8, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plozasiran

Start the discussion